Tesamorelin

Tesamorelin is a synthetic peptide. It is a growth hormone-releasing hormone (GHRH) analog composed of 44 amino acids, used primarily to treat HIV-associated lipodystrophy by reducing visceral adipose tissue (abdominal fat).

Key Benefits of Using Tesamorelin

• May help reduce excess abdominal fat by supporting natural growth hormone release
• Commonly researched for improving body composition and lean muscle preservation
• May support better metabolic function and healthy lipid levels
• Research suggests potential benefits for energy, recovery, and cognitive support

FDA-Approved Uses

SINGLE FDA-APPROVED INDICATION:

1. HIV-Associated Lipodystrophy
The ONLY FDA-approved medication in the US to reduce excess abdominal (visceral) fat in HIV-infected adults with lipodystrophy caused by antiretroviral therapy (ART).

Approval criteria:
– HIV-infected adults on antiretroviral treatment
– Confirmed excess visceral adipose tissue (VAT >130 cm² by CT scan)
– Waist circumference ≥95 cm (men) or ≥94 cm (women)
– Failed reduction of excess VAT through diet and exercise

⚠️ NOT indicated for general weight loss (weight-neutral outside lipodystrophy).
⚠️ NOT approved for pediatric use.

Off-label uses (not FDA-approved):
– Cognitive function in older adults (Phase 2 data only)
– Body composition in non-HIV adults (anti-aging/wellness)

Trade Names in the USA and Manufacturers

FDA-Approved Brands (both by Theratechnologies Inc.):

1. Egrifta SV (tesamorelin 2 mg/vial)
FDA approved: October 19, 2019
Single-dose vials; reconstituted daily

2. Egrifta WR (tesamorelin 11.6 mg/vial)
FDA approved: March 25, 2025
Weekly reconstitution; 7 daily doses per vial
Requires <50% injection volume vs Egrifta SV
Bioequivalent to original formulation

⚠️ Egrifta SV and Egrifta WR are NOT substitutable.
No FDA-approved generic as of May 2026.
Compounded tesamorelin available from licensed 503A/503B pharmacies with prescription.

Dosage

FDA-Approved Dosing:

Egrifta SV (2 mg/vial):
2 mg subcutaneously once daily
Reconstitute with 2.1 mL Sterile Water for Injection
Rotate injection sites within abdomen
Do not inject into scar tissue, bruises, or navel

Egrifta WR (11.6 mg/vial):
1.28 mg (0.16 mL) subcutaneously once daily
Reconstitute with 1.3 mL Bacteriostatic Water for Injection
Concentration: 8 mg/mL; 1 vial = 7 daily doses

No dose titration — full dose from day 1
Discontinue if no VAT response after 6 months
Monitor IGF-1 and fasting glucose during treatment

Off-label adult compounded dosing (not FDA-approved):
1–2 mg subcutaneously once daily
Some protocols: 60–90 day on / 30 day off cycles

Pricing

Without insurance:
Egrifta SV / WR: ~$2,400–$2,800/month

With insurance (prior auth required):
Specialty Tier 4/5; out-of-pocket varies by plan

THERA Patient Support Program:
Theratechnologies offers PA navigation and copay assistance for eligible patients

Compounded tesamorelin:
503A pharmacy: ~$150–$300/month (cash only)
503B outsourcing facility: ~$800–$1,200/month

Coverage by Insurance Type

1. ACA Marketplace
HIV-lipodystrophy: Varies; prior auth required ⚠️
Off-label: Not covered ❌

2. Employer/Commercial Insurance
HIV-lipodystrophy: Covered with strict prior auth ⚠️
Requires: HIV+ diagnosis + imaging-confirmed VAT + documented diet/exercise failure
Off-label: Not covered ❌

3. Medicare Part D
HIV-lipodystrophy: Specialty tier; covered with prior auth ⚠️
Off-label: Not covered ❌

4. Medicaid
HIV-lipodystrophy: Varies by state; prior auth typically required ⚠️

5. TRICARE
HIV-lipodystrophy: Covered with prior auth ⚠️

6. Ryan White HIV/AIDS Program / ADAP
May assist eligible HIV+ patients with costs ✅

Tips

– Tesamorelin is the ONLY FDA-approved drug for HIV-lipodystrophy — no approved generic or alternative.
– For insurance: provide CT-confirmed VAT documentation, HIV+ status, and diet/exercise failure records.
– Contact THERA support program (Theratechnologies) for prior auth assistance and copay help.
– Ryan White ADAP programs can help cover costs for eligible HIV+ patients.
– Egrifta WR (2025) needs only weekly reconstitution vs Egrifta SV’s daily — ask about switching.
– Monitor IGF-1 and fasting blood glucose during treatment.
– Fat reduction effects are NOT maintained after stopping — VAT returns to baseline within ~12 weeks. Ongoing treatment required.

Side Effects

Common (FDA prescribing information):
– Arthralgia (joint pain) — most common
– Injection site reactions (erythema, pruritus, pain, swelling)
– Pain in extremities
– Peripheral edema
– Myalgia (muscle pain)

Less common:
– Elevated fasting blood glucose / insulin resistance worsening
– Elevated IGF-1 levels (long-term cancer risk not fully established)
– Fluid retention / carpal tunnel-like symptoms
– Nausea, vomiting, abdominal pain
– Paresthesia

Rare/Serious:
– Antibody formation (~56% at 26 weeks; did not significantly impact efficacy)
– Potential cancer risk: elevated IGF-1 associated with some cancers; no increased incidence in trials
– Hydrocephaly in animal studies at ~2x clinical dose
– Hypersensitivity reactions

Contraindications

Absolute contraindications (FDA):
– Active malignancy — any cancer; prior cancer must be complete and inactive
– Pregnancy — animal studies show fetal harm; discontinue immediately if pregnant
– Disruption of hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor/surgery, head trauma affecting pituitary)
– Known hypersensitivity to tesamorelin or any excipient

Use with caution:
– Diabetes mellitus: not studied in T1DM, T2DM, or patients on insulin/oral hypoglycemics
– Children with open epiphyses: not recommended
– Breastfeeding: HIV+ mothers advised not to breastfeed; no human milk data
– Glucocorticoid replacement therapy: GH stimulation may alter cortisol conversion

Pharmacology

Synthetic analogue of endogenous human GHRH (Growth Hormone-Releasing Factor). 44-amino acid polypeptide — full sequence of human GRF — with a trans-3-hexenoyl (C6) moiety attached at the N-terminal tyrosine.

This modification improves plasma stability vs. native GHRH (which is rapidly cleaved by dipeptidyl peptidase IV). MW ~5,135.9 Daltons (free base). Provided as sterile lyophilized powder for reconstitution. Administered subcutaneously once daily. Binds and stimulates human GRF receptors with similar potency to endogenous GRF.

Mechanism of action

Tesamorelin binds to GHRH receptors (GHRHR) on pituitary somatotroph cells → activates adenylyl cyclase → increases intracellular cAMP → stimulates synthesis and pulsatile GH release from anterior pituitary.

• GH is both anabolic and lipolytic. Effects via GH receptors on:
• Adipocytes: promotes lipolysis, especially visceral/abdominal fat
• Hepatocytes: stimulates IGF-1 production
• Myocytes: promotes protein synthesis
• Chondrocytes/osteoblasts: promotes bone growth

In HIV lipodystrophy:

• ART impairs GH secretion → accumulation of VAT
• Tesamorelin restores GH pulsatility → increases visceral fat lipolysis
• Effects are not maintained after stopping (~12 weeks to return to baseline)

Result Claims from Different Companies

Theratechnologies Inc. (Phase 3 pivotal trials):

• LIPO-010 + CTR-1011 pooled analysis (J Clin Endocrinol Metab, 2010):
• 14–18% VAT reduction vs. placebo at 26 weeks
• Reduction in waist circumference ~1.5–2 cm vs. placebo
• Significant IGF-1 increase confirming GH stimulation
• Triglyceride improvements in patients with ≥8% VAT reduction

– 2026 Meta-analysis (Badran et al., 5 RCTs):
Mean VAT reduction: 27.71 cm²
Mean trunk fat reduction: 1.18 kg
Mean lean body mass increase: 1.42 kg

Off-label adult/cognitive claims (Phase 2, not FDA-verified):
Improvements in verbal memory and cognitive function in adults aged 55–87 (1 mg/day, 20 weeks)

Disclaimer

This content about “Tesamorelin” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.